低分子肝素治疗肾病综合征患者高凝状态的实验室观察

目的：观察低分子肝素对肾病综合征（N S ）患者继发高凝状态的疗效。方法将87例 N S患者分为常规治疗组（n＝42）和低分子肝素治疗组（n＝45），应用泼尼松对常规治疗组的患者进行治疗，应用低分子肝素联合泼尼松对低分子肝素治疗组的患者进行治疗，对两组患者治疗前后相关的凝血指标进行检测、临床治疗效果进行分析。结果常规治疗组治疗后，患者凝血相关指标与治疗前比较差异无统计学意义（P＞0．05），低分子肝素治疗组治疗后患者凝血酶原时间、活化部分凝血活酶时间与治疗前比较明显延长，D‐二聚体、纤维蛋白原浓度较治疗前明显下降，抗凝血酶Ⅲ浓度与治疗前比较明显增加，差异有统计学意义（P＜0．05）；低分子肝素治疗组患者在治疗后均未有出血现象。结论低分子肝素联合泼尼松能减轻NS继发的高凝状态，且未出现出血现象，具有较为显著的临床疗效。

Laboratory observation on low molecular heparin for treating high coagulation state in patients with nephrotic syndrome

Objective To observe the curative effect of low molecular heparin for treating secondary high coagulation state in the patients with nephrotic syndrome(NS) .Methods Total 87 cases of NS in our hospital were divided into the conventional treat‐ment group (n=42) and the low molecular heparin treatment group (n=45) .The routine treatment group was given the prednisone treatment and the low molecular heparin treatment group was treated by low molecular heparin combined with prednisone .The re‐lated indicators of blood coagulation before and after treatment were detected and the clinical curative effects in two groups were an‐alyzed .Results The coagulation related indicators in the conventional treatment group had no statistically significant difference be‐tween before and after treatment (P>0 .05) ,the prothrombin time(PT) and activated partial thrombin time(APTT) after treat‐ment in the low molecular heparin treatment group were significantly extended compared with before treatment ,while the concen‐trations of D‐dimer and fibrinogen were significantly decreased and the concentration of antithrombin Ⅲ was markedly increased compared with before treatment ,showing statistically significant differences between the two groups (P<0 .05);the patients of the low molecular heparin group patients had no bleeding after treatment .Conclusion Low molecular heparin combined with predni‐sone can reduce the secondary high condensation state in NS without bleeding and has a significantly clinical effect .